CN104355989B - 一种苹果酸镁的制备方法 - Google Patents
一种苹果酸镁的制备方法 Download PDFInfo
- Publication number
- CN104355989B CN104355989B CN201410594008.5A CN201410594008A CN104355989B CN 104355989 B CN104355989 B CN 104355989B CN 201410594008 A CN201410594008 A CN 201410594008A CN 104355989 B CN104355989 B CN 104355989B
- Authority
- CN
- China
- Prior art keywords
- malic acid
- magnesium
- magnesium salt
- acid magnesium
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- JFQQIWNDAXACSR-UHFFFAOYSA-L magnesium malate Chemical compound [Mg+2].[O-]C(=O)C(O)CC([O-])=O JFQQIWNDAXACSR-UHFFFAOYSA-L 0.000 title claims abstract description 31
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims abstract description 16
- 239000001095 magnesium carbonate Substances 0.000 claims abstract description 16
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims abstract description 16
- 239000000395 magnesium oxide Substances 0.000 claims abstract description 16
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims abstract description 16
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229940116298 l- malic acid Drugs 0.000 claims abstract description 15
- 238000003756 stirring Methods 0.000 claims abstract description 11
- 238000001914 filtration Methods 0.000 claims abstract description 10
- 239000013078 crystal Substances 0.000 claims abstract description 9
- 239000008367 deionised water Substances 0.000 claims abstract description 9
- 229910021641 deionized water Inorganic materials 0.000 claims abstract description 9
- 239000000706 filtrate Substances 0.000 claims abstract description 9
- 238000010792 warming Methods 0.000 claims abstract description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 9
- 238000004042 decolorization Methods 0.000 claims abstract description 6
- 238000002425 crystallisation Methods 0.000 claims abstract description 5
- 230000008025 crystallization Effects 0.000 claims abstract description 5
- 238000000034 method Methods 0.000 claims abstract description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 12
- 230000009920 chelation Effects 0.000 abstract description 11
- 239000000047 product Substances 0.000 abstract description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 10
- 239000011777 magnesium Substances 0.000 description 10
- 229910052749 magnesium Inorganic materials 0.000 description 10
- 239000007788 liquid Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 229910001220 stainless steel Inorganic materials 0.000 description 4
- 239000010935 stainless steel Substances 0.000 description 4
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 3
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 3
- 229940099690 malic acid Drugs 0.000 description 3
- 239000001630 malic acid Substances 0.000 description 3
- 235000011090 malic acid Nutrition 0.000 description 3
- 208000008167 Magnesium Deficiency Diseases 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 235000004764 magnesium deficiency Nutrition 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 230000005961 cardioprotection Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000012372 quality testing Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/41—Preparation of salts of carboxylic acids
- C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/42—Separation; Purification; Stabilisation; Use of additives
- C07C51/43—Separation; Purification; Stabilisation; Use of additives by change of the physical state, e.g. crystallisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/42—Separation; Purification; Stabilisation; Use of additives
- C07C51/47—Separation; Purification; Stabilisation; Use of additives by solid-liquid treatment; by chemisorption
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Crystallography & Structural Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
本发明公开一种苹果酸镁的制备方法,用无离子水将L‑苹果酸溶解后,升温至75~85℃后,逐步分批加入碳酸镁或氧化镁,然后加热至105~120℃,搅拌至碳酸镁或氧化镁完全溶解,将反应溶液脱色过滤,滤液减压浓缩结晶得到苹果酸镁晶体。本发明方法生产的苹果酸镁螯合率显著提高,能显著提高产品的质量。
Description
技术领域:
本发明属于化工领域,具体涉及一种苹果酸镁的制备方法。
技术背景:
苹果酸镁是人体镁的最好来源,在补充镁的同时还附加了苹果酸。CAS:869-06-7,性状为白色粉末,是一种营养强化剂。
镁是人体(含动物)必需的基本元素,阳离子镁具有壮骨、健牙、消炎、镇痛、维持神经与肌肉的正常兴奋性,有治过敏性疾病的功效。镁几乎参与人体所有的新陈代谢过程,在细胞内它的含量仅次于钾。镁影响钾、钠、钙离子细胞内外移动的“通道”,并有维持生物膜电位的作用。镁元素的缺乏,必然会对人体健康造成危害。缺镁易引发心血管疾病:现代医学证实,镁对心脏活动具有重要的调节作用。它通过对心肌的抑制,使心脏的节律和兴奋传导减弱,从而有利于心脏的舒张与休息。若体内缺镁,会引起供应心脏血液和氧气的动脉痉挛,容易导致心脏聚停而突然死亡。另外,镁对心血管系统亦有很好的保护作用,它可减少血液中胆固醇的含量,防止动脉硬化,同时还能扩张冠状动脉,增加肌供血量。而且,镁能在供血骤然受阻时保护心脏免受伤害,从而降低心脏病突发死亡率。苹果酸是食品风味酸络合剂。现有技术制备苹果酸镁纯度低,螯合率低,产量低、生产成本高。鉴于苹果酸镁的巨大应用前景,需要开发新的生产方法以提高苹果酸镁的螯合率和质量。
发明内容:
本发明的目的在于提供一种苹果酸镁的制备方法。
本发明的目的通过以下技术方案实现:
一种苹果酸镁的制备方法,用无离子水将L-苹果酸溶解后,升温至75~85℃,逐步分批加入碳酸镁或氧化镁,然后加热至105~120℃,搅拌至碳酸镁或氧化镁完全溶解,将反应溶液脱色过滤,滤液减压浓缩结晶得到苹果酸镁晶体。
所述的L-苹果酸与碳酸镁或氧化镁的摩尔比优选为1.1~1.3:1。
逐步分批加入碳酸镁或氧化镁后优选加热至110~120℃。
所述的反应溶液中加入活性炭脱色过滤。
所述的L-苹果酸与无离子水的质量体积比优选为320~400g/L。
所述的滤液减压浓缩至原体积的2/5结晶得到苹果酸镁晶体。
L-苹果酸与碳酸镁或氧化镁的摩尔比以及反应温度显著影响苹果酸镁的螯合率及收率,同时也显著影响制备工艺的成本。
而本发明技术方案中,L-苹果酸与碳酸镁(氧化镁)反应的摩尔比为1.1~1.3:1,反应温度为105~120℃。这样在整个生产过程中反应溶液能够完全清澈,减压浓缩前无固体析出,中和反应完全进行,更重要的是螯合效果非常好,能达到98%以上。
L-苹果酸与碳酸镁或氧化镁反应的摩尔比为1:1,反应温度为60~80℃的反应条件,在生产过程中会出现碳酸镁或者是氧化镁未完全溶解时,苹果酸镁已经析出,从而导致中和反应不完全,更重要的是反应的效果不好,螯合率比较低,一般在50%~60%。
本发明的有益效果:
本发明方法生产的苹果酸镁螯合率显著提高,能显著提高产品的质量。
具体实施方式:
为了使本发明的目的、技术方案及优点更加清楚明白,以下结合实施例,对本发明进行进一步详细说明。应当理解,此处所描述的具体实施例仅用以解释本发明,并不用于限定本发明,凡在本发明的构思前提下对本发明制备方法的简单改进都属于本发明的保护范围之内。
实施例1:
在10L不锈钢反应釜中加入L-苹果酸:1.98kg(14.8mol),无离子水:6L,搅拌全部溶解后,升温至80℃,逐步分批加入氧化镁0.54kg(13.4mol)。投料完毕后升温至110℃,搅拌至完全溶解。向反应溶液中加入活性炭100g,脱色过滤,滤液减压浓缩至原体积的2/5,析出大量的苹果酸镁白色结晶。抽滤:母液套用至下批配料使用,固体60℃~70℃烘干。
得到苹果酸镁:2.40kg。收率:93.02%,母液套用可以达到:96%。螯合率为:98.7%。
实施例2:
在10L不锈钢反应釜中加入L-苹果酸:2.16kg(16.1mol),无离子水:6L,搅拌全部溶解后,升温至80℃,逐步分批加入碳酸镁1.14kg(13.5mol)。投料完毕后升温至110℃,搅拌至完全溶解。向反应溶液中加入活性炭100g,脱色过滤,滤液减压浓缩至原体积的2/5,析出大量的苹果酸镁白色结晶。抽滤:母液套用至下批配料使用,固体60℃~70℃烘干。
得到苹果酸镁:2.30kg。收率:89.14%,母液套用可以达到:95%。螯合率为:99.1%。
实施例3:
在10L不锈钢反应釜中加入L-苹果酸:2.34kg(17.5mol),无离子水:6L,搅拌全部溶解后,升温至80℃,逐步分批加入碳酸镁1.14kg(13.5mol)。投料完毕后加温至120℃,搅拌至完全溶解。向反应溶液中加入活性炭100g,脱色过滤,滤液减压浓缩至原体积的2/5,析出大量的苹果酸镁白色结晶。抽滤:母液套用至下批配料使用,固体60℃~70℃烘干。
得到苹果酸镁:2.15kg。收率:83.33%,母液套用可以达到:95%。螯合率为:99.4%。
比较例1:
在10L不锈钢反应釜中加入L-苹果酸:1.795kg(13.4mol),无离子水:6L,搅拌全部溶解后,升温至80℃,逐步分批加入氧化镁0.54kg(13.4mol)。投料完毕后搅拌至完全溶解。向反应溶液中加入活性炭100g,脱色过滤,滤液减压浓缩至原体积的2/5,析出大量的苹果酸镁白色结晶。抽滤:母液套用至下批配料使用,固体60℃~70℃烘干。
得到苹果酸镁:2.43kg。收率:94.6%,母液套用可以达到:97%。螯合率为:53%。
表1 实施例1~3及比较例1的成品质量检测结果
标准 | 实施例1 | 实施例2 | 实施例3 | 比较例1 |
pH=4.8---5.0 | 4.93 | 4.90 | 4.88 | 4.98 |
旋光:-1.75-1.95 | -1.85 | -1.85 | -1.83 | -1.78 |
SO4 2-≤200ppm | ≤150ppm | ≤150ppm | ≤150ppm | ≤150ppm |
CL-≤200ppm | ≤100ppm | ≤100ppm | ≤100ppm | ≤100ppm |
Fe≤10ppm | ≤3ppm | ≤3ppm | ≤3ppm | ≤3ppm |
Mg2+=9.9-10.3% | Mg2+=10.16% | Mg2+=10.14% | Mg2+=10.13% | Mg2+=10.13% |
透光:98-100% | 99% | 99% | 98.5% | 99% |
结果显示:实施例1~3中随着苹果酸比例的提高,苹果酸镁的一步收率相应有所降低;随着反应温度的升高,产品的透光率有所降低。比较例中L-苹果酸与碳酸镁或氧化镁反应的摩尔比为1:1时,苹果酸镁的收率虽然与实施例1~3差别不大,但是螯合率却明显低于实施例1~3,只有53%。
Claims (4)
1.一种苹果酸镁的制备方法,其特征在于用无离子水将L-苹果酸溶解后,升温至75~85℃,逐步分批加入碳酸镁或氧化镁,然后加热至110~120℃,搅拌至碳酸镁或氧化镁完全溶解,将反应溶液脱色过滤,滤液减压浓缩结晶得到苹果酸镁晶体;所述的L-苹果酸与碳酸镁或氧化镁的摩尔比为1.1~1.3:1。
2.根据权利要求1所述的方法,其特征在于所述的反应溶液中加入活性炭脱色过滤。
3.根据权利要求1所述的方法,其特征在于所述的L-苹果酸与无离子水的质量体积比为320~400g/L。
4.根据权利要求1所述的方法,其特征在于所述的滤液减压浓缩至原体积的2/5结晶得到苹果酸镁晶体。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410594008.5A CN104355989B (zh) | 2014-10-29 | 2014-10-29 | 一种苹果酸镁的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410594008.5A CN104355989B (zh) | 2014-10-29 | 2014-10-29 | 一种苹果酸镁的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104355989A CN104355989A (zh) | 2015-02-18 |
CN104355989B true CN104355989B (zh) | 2016-09-14 |
Family
ID=52523328
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410594008.5A Expired - Fee Related CN104355989B (zh) | 2014-10-29 | 2014-10-29 | 一种苹果酸镁的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104355989B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105621460A (zh) * | 2015-12-31 | 2016-06-01 | 王丰登 | 一种无水镁盐的生产方法 |
CN112457184A (zh) * | 2020-12-23 | 2021-03-09 | 河南瑞贝佳生物科技有限公司 | 一种富马酸镁的制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002032235A2 (en) * | 2000-10-19 | 2002-04-25 | Nutrapure, Inc. | Process for making mineral, food or pharmaceutical grade salt products |
CN102783691A (zh) * | 2012-08-20 | 2012-11-21 | 李志林 | 一种钙镁制氢剂 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6589555B2 (en) * | 1999-12-29 | 2003-07-08 | Mahendra Pandya | Effervescent vitaceutical compositions and related methods |
US7351853B2 (en) * | 2006-01-23 | 2008-04-01 | Albion Advanced Nutrition | Method of manufacturing a granular mineral composition |
-
2014
- 2014-10-29 CN CN201410594008.5A patent/CN104355989B/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002032235A2 (en) * | 2000-10-19 | 2002-04-25 | Nutrapure, Inc. | Process for making mineral, food or pharmaceutical grade salt products |
CN102783691A (zh) * | 2012-08-20 | 2012-11-21 | 李志林 | 一种钙镁制氢剂 |
Also Published As
Publication number | Publication date |
---|---|
CN104355989A (zh) | 2015-02-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101429221B (zh) | 一种制备d-氨基葡萄糖盐酸盐的方法 | |
EP3208259B1 (en) | Preparation method for polyunsaturated fatty acid-calcium | |
CN104355989B (zh) | 一种苹果酸镁的制备方法 | |
CN102939281A (zh) | 格隆氯铵的制备方法 | |
CN105085362B (zh) | 高纯度结晶型阿托伐他汀钙的制备方法 | |
CN104116106A (zh) | 一种天然枸杞山楂醋饮料及其制作方法 | |
CN103242364B (zh) | 磷酸肌酸钠的制备方法 | |
CN104086395B (zh) | 以贝壳为原料制备的果酸螯合钙产品及方法 | |
CN101891172A (zh) | 一种食品级磷酸氢二钠的制备方法 | |
CN109280015A (zh) | 一种d-泛酸钠合成和手性拆分方法 | |
CN102838512A (zh) | 肌酸硝酸盐的制备方法 | |
JP2003221362A (ja) | クエン酸及びクエン酸カルシウム、並びにその製造方法 | |
CN109422793A (zh) | 一种联合提取猪去氧胆酸与鹅去氧胆酸的方法 | |
CN104860812B (zh) | 一种乳酸铵固体的制备方法 | |
US7208615B2 (en) | Triple mineral salts of (-)-hydroxycitric acid and processes for preparing the same | |
AU2018101422A4 (en) | Coagulant anhydrous ammonium sulphate production plant | |
CN109942643A (zh) | 一种蔗糖脂肪酸酯的提纯分离方法 | |
CN109942410A (zh) | 一种高纯苹果酸镁的制备方法 | |
CN103787870A (zh) | 一种柠檬酸钠易炭化物的去除方法 | |
CN101844991B (zh) | L-亮氨酸硝酸盐的制备方法 | |
EP3385250B1 (en) | Crystals of monovalent cation salt of 3-hydroxyisovaleric acid, and method for producing said crystals | |
CN103172532B (zh) | 一种乙二胺四醋酸钙二钠的制备方法 | |
CN106632174A (zh) | 牛磺酸抗坏血酸氢钙及其制备方法和应用 | |
CN207418313U (zh) | 膨松剂铵矾的生产装置 | |
CN108238907A (zh) | 2-(4-异丁基苯基)丙酸药物合成方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160914 |